Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Executive summary

Onvuzosiran efficacy and safety

3 evidence topics · 15 sources

Summary: phase 1/2 pharmacodynamics, efficacy, and safety

Onvuzosiran (ADX-324) has been studied in one phase 1/2 trial (ADX-324-101, NCT05691361), a single-center study in Australia. Part A was a randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers, with weight-based doses from 0.4 to 6 mg/kg and one cohort that received two 140 mg doses 3 months apart. Part B is an open-label phase 2a study in 3 participants with type I or type II HAE, dosed every 6 months: 1 participant received 122.5 mg and 2 received 245 mg. These doses are lower or less frequent than the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months.

In an interim analysis of Part A, mean nadir prekallikrein levels were 39% (n=6), 14% (n=6), and 20% (n=5) of baseline after single doses of 0.4, 1.0, and 2.0 mg/kg. The prospectus reports for the 6 mg/kg cohort a mean prekallikrein-kallikrein reduction of 94% (88% to 97%) at nadir and 84% (78% to 92%) at 6 months, with 3 of the 4 participants below the lower limit of quantification at nadir. For a single dose of 300 mg plus or minus 25 mg (n=5 in the AAAAI poster), the prospectus reports a mean reduction exceeding 90% (84% to 96%) at nadir and at least 80% (65% to 90%) through Day 169; the AAAAI poster and the February 2026 press release report 93% at nadir and 80% at 6 months. The sponsor reports a lag of about 22 days between the first dose and full inhibition, and states that reductions in the participants with HAE were similar to those in healthy volunteers at similar doses.

All 3 phase 2a participants were attack-free for 3 months after the first dose. The prospectus reports one participant attack-free for 18 consecutive months on every-6-month dosing after one mild attack on Day 153 (August 19, 2026 cutoff); the November 2026 presentation reports Patient 202 (245 mg every 6 months) attack-free for 21 consecutive months after one mild attack on Day 153 (November 5, 2026 cutoff). Neither document states whether the two reports describe the same participant. All phase 2a dosing was every 6 months; the November 2026 presentation describes the 3-month result as a “100% Q3M attack-free rate”. Sponsor documents state that no attacks occurred while the prekallikrein-kallikrein reduction exceeded 80%. No baseline attack rates, on-treatment attack rates, baseline characteristics, or quality-of-life results were identified.

In the Part A interim analysis, no serious adverse events were reported, all study drug-related adverse events were mild except one moderate event, and headache was the most frequent adverse event. The prospectus lists injection site reactions, headache, laboratory changes in blood creatine phosphokinase, and ALT/AST increases as the most common adverse events in Part A, and describes the laboratory changes as asymptomatic, transient, and resolved without treatment; it gives no counts for them. A workshop abstract names headache and injection-site reaction as the most common adverse events in Part A and gives one figure, 28.9%, without stating whether it applies to each event or to both together. No Part A participant had a serious adverse event or an adverse event leading to withdrawal. In Part B, no treatment-related serious adverse events were reported as of the August 5, 2026 safety cutoff, repeat dosing at 6-month intervals was not associated with a safety signal, and 1 of the 3 participants withdrew for administrative reasons.

The results are available only in congress abstracts, congress posters, a press release, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, and the registry record shows “No Results Posted”.

Summary: differences between reporting documents

The documents report different numbers of Part A participants: 43 (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 press release, and 49 (38 onvuzosiran, 11 placebo) in the prospectus and the AAAAI poster; the EAACI poster also cites 49 healthy volunteers. Planned registry enrollment for both parts is 53. The number of Part A cohorts is given as seven in the prospectus, 6 dose-escalation cohorts plus 1 repeat-dose cohort in the workshop abstract, and 5 doses plus a repeat-dosing group in the EAACI abstract.

The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort. The November 2026 presentation attributes the 94% and 84% means to 6 mg/kg on one page and the same means with their ranges to 300 mg plus or minus 25 mg on another, whereas the prospectus reports exceeding 90% and at least 80% for that fixed dose, and the AAAAI poster and February 2026 release report 93% and 80%.

The proposed suppression threshold for attack prevention is greater than 80% in the prospectus, the November 2026 presentation, and the AAAAI, EAACI, and ACAAI abstracts, and greater than 70% in the workshop abstract. The first Part B dose is written as 122 mg, 122.5 mg, or 2 mg/kg (approximately 125 mg). Serious adverse events are described as absent, absent when treatment-related, or absent when drug-related, depending on the document.

Summary: phase 3 trial status

STOP-HAE (NCT06960213) is a randomized, double-blind, placebo-controlled phase 3 trial that began in August 2025 and plans to enroll approximately 90 adults with type I or type II HAE at 70 sites (the EAACI 2026 poster reports at least 60 sites in 22 countries). Participants are randomized 1:1:1 to onvuzosiran 300 mg every 6 months, 240 mg every 3 months, or placebo. The primary endpoint is the time-normalized number of investigator-confirmed attacks per month from Day 22 to Week 25 for 300 mg every 6 months compared with placebo. No results are available; primary completion is estimated for 2027-11-30, and the sponsor expects topline data by year-end 2027. The sponsor's target profile is a greater than 90% reduction in monthly attacks with greater than 75% of patients attack-free. Participants who complete STOP-HAE may enter the extension study ADX-324-302 (NCT07428499), which began on 2026-04-02, gives onvuzosiran for up to 3 years to approximately 90 participants, has the incidence and severity of treatment-emergent adverse events through Month 36 as its primary endpoint, and has an estimated primary completion date of 2030-06-30.